Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer
Clinical and epidemiological evidence shows associations between cancer and type 2 diabetes mellitus (DM2). These diseases share some common pathophysiological mechanisms. Aim: To study in a population of older adults whether the presence of DM2 affects the epidemiological parameters o...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/42713 |
| Aporte de: |
| id |
I10-R327-article-42713 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
cáncer Diabetes Mellitus Type 2 older adults Epidemiology cáncer Diabetes Mellitus Tipo 2 Adultos Mayores epidemiologia |
| spellingShingle |
cáncer Diabetes Mellitus Type 2 older adults Epidemiology cáncer Diabetes Mellitus Tipo 2 Adultos Mayores epidemiologia Díaz-Gerevini, GT Priotto, S Díaz, M López, CB Pigino, G Quiroga, P Repossi, G Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| topic_facet |
cáncer Diabetes Mellitus Type 2 older adults Epidemiology cáncer Diabetes Mellitus Tipo 2 Adultos Mayores epidemiologia |
| author |
Díaz-Gerevini, GT Priotto, S Díaz, M López, CB Pigino, G Quiroga, P Repossi, G |
| author_facet |
Díaz-Gerevini, GT Priotto, S Díaz, M López, CB Pigino, G Quiroga, P Repossi, G |
| author_sort |
Díaz-Gerevini, GT |
| title |
Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| title_short |
Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| title_full |
Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| title_fullStr |
Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| title_full_unstemmed |
Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| title_sort |
epidemiology in older adults of the comorbidity of type 2 diabetes and cancer |
| description |
Clinical and epidemiological evidence shows associations between cancer and type 2 diabetes mellitus (DM2). These diseases share some common pathophysiological mechanisms. Aim: To study in a population of older adults whether the presence of DM2 affects the epidemiological parameters of cancer.
Retrospective observational epidemiological study (2006-2017), analysis of 4,574 medical records of patients (≥65 years), Centro San Ricardo Pampuri (Va. Carlos Paz, Córdoba). Cancer patients were grouped: with DM2 and without DM2. The following were calculated and compared: prevalence, mortality, lethality and survival for each group. Data were analyzed with Infostat using ANOVA (continuous variables) and chi-square (categorical), p≤0.05. Confidentiality and anonymity were respected.
Population data: 56% women/44% men. 42% of the total population suffered from obesity and 39.8% DM2. 390 cancer patients in the period. General cancer prevalence=8.5%, mortality=27.5 ‰, lethality=32%. Average survival: 2544.44 days. Prevalences between patients with and without DM2, and between the sexes were similar, but higher in obese patients (58 vs 42%). Most frequent tumors: female: breast (0.44) and colon (0.10); male: prostate (0.36) and colon (0.17). Comparisons between patients with and without DM2: -Prevalence (‰): -Older in the group with DM2: Men: pancreas (1.31vs0.44), kidney (1.31vs0.44) and non-Hodgkin lymphoma (0.87vs0.44); Women: breast (11.15vs8.31), pancreas (1.75vs0) and endometrium (1.53vs0.87). -Higher in the group without DM2: Men: prostate (7vs4.37), colon (3.28vs2.84) and bladder (1.97vs0.87); Women: colon (3.06vs1.31), thyroid (1.09vs0.44) and melanoma (1.09vs0.22). –Age at diagnosis (years): colon cancer (68.91vs75.87) and prostate cancer (71.78vs77.74) were found at earlier ages in men with DM2. –Mortality: The values were similar in women with and without DM2 (RR:1.01; OR:1.02). In men it was lower for DM2 (RR:0.74; OR:0.57). Those with the highest mortality in patients with DM2 were: breast>colon>prostate>pancreas. –Lethality (%): higher in DM2 patients for gastric cancer (100vs50), while esophagus, colon, kidney and prostate were higher in the group without DM2. –Survival (days): women without DM2 have a higher survival (4213.5vs1802.73).
The existence of DM2 in comorbidity with cancer significantly affects the parameters studied, mainly in women, since breast cancer had a higher prevalence in women with DM2, and these had a lower survival.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2023 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/42713 |
| work_keys_str_mv |
AT diazgerevinigt epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT priottos epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT diazm epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT lopezcb epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT piginog epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT quirogap epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT repossig epidemiologyinolderadultsofthecomorbidityoftype2diabetesandcancer AT diazgerevinigt epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer AT priottos epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer AT diazm epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer AT lopezcb epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer AT piginog epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer AT quirogap epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer AT repossig epidemiologiaenadultosmayoresdelacomorbilidaddediabetestipo2ycancer |
| first_indexed |
2024-09-03T21:04:52Z |
| last_indexed |
2024-09-03T21:04:52Z |
| _version_ |
1809210400740212736 |
| spelling |
I10-R327-article-427132023-10-19T21:19:43Z Epidemiology in older adults of the comorbidity of type 2 diabetes and cancer Epidemiología en adultos mayores de la comorbilidad de diabetes tipo 2 y cáncer Díaz-Gerevini, GT Priotto, S Díaz, M López, CB Pigino, G Quiroga, P Repossi, G cáncer Diabetes Mellitus Type 2 older adults Epidemiology cáncer Diabetes Mellitus Tipo 2 Adultos Mayores epidemiologia Clinical and epidemiological evidence shows associations between cancer and type 2 diabetes mellitus (DM2). These diseases share some common pathophysiological mechanisms. Aim: To study in a population of older adults whether the presence of DM2 affects the epidemiological parameters of cancer. Retrospective observational epidemiological study (2006-2017), analysis of 4,574 medical records of patients (≥65 years), Centro San Ricardo Pampuri (Va. Carlos Paz, Córdoba). Cancer patients were grouped: with DM2 and without DM2. The following were calculated and compared: prevalence, mortality, lethality and survival for each group. Data were analyzed with Infostat using ANOVA (continuous variables) and chi-square (categorical), p≤0.05. Confidentiality and anonymity were respected. Population data: 56% women/44% men. 42% of the total population suffered from obesity and 39.8% DM2. 390 cancer patients in the period. General cancer prevalence=8.5%, mortality=27.5 ‰, lethality=32%. Average survival: 2544.44 days. Prevalences between patients with and without DM2, and between the sexes were similar, but higher in obese patients (58 vs 42%). Most frequent tumors: female: breast (0.44) and colon (0.10); male: prostate (0.36) and colon (0.17). Comparisons between patients with and without DM2: -Prevalence (‰): -Older in the group with DM2: Men: pancreas (1.31vs0.44), kidney (1.31vs0.44) and non-Hodgkin lymphoma (0.87vs0.44); Women: breast (11.15vs8.31), pancreas (1.75vs0) and endometrium (1.53vs0.87). -Higher in the group without DM2: Men: prostate (7vs4.37), colon (3.28vs2.84) and bladder (1.97vs0.87); Women: colon (3.06vs1.31), thyroid (1.09vs0.44) and melanoma (1.09vs0.22). –Age at diagnosis (years): colon cancer (68.91vs75.87) and prostate cancer (71.78vs77.74) were found at earlier ages in men with DM2. –Mortality: The values were similar in women with and without DM2 (RR:1.01; OR:1.02). In men it was lower for DM2 (RR:0.74; OR:0.57). Those with the highest mortality in patients with DM2 were: breast>colon>prostate>pancreas. –Lethality (%): higher in DM2 patients for gastric cancer (100vs50), while esophagus, colon, kidney and prostate were higher in the group without DM2. –Survival (days): women without DM2 have a higher survival (4213.5vs1802.73). The existence of DM2 in comorbidity with cancer significantly affects the parameters studied, mainly in women, since breast cancer had a higher prevalence in women with DM2, and these had a lower survival. Evidencia clínica y epidemiológica muestra asociaciones entre cáncer y diabetes mellitus tipo 2 (DM2). Estas enfermedades comparten algunos mecanismos fisiopatológicos comunes. Objetivo: Estudiar en una población de adultos mayores si la presencia de DM2 afecta los parámetros epidemiológicos del cáncer. Trabajo epidemiológico observacional retrospectivo (2006-2017), análisis de 4574 historias clínicas de pacientes (≥65 años), Centro San Ricardo Pampuri (Va. Carlos Paz, Córdoba). Los pacientes con cáncer se agruparon: con DM2 y sin DM2. Se calcularon y compararon: prevalencia, mortalidad, letalidad y sobrevida para cada grupo. Se analizaron los datos con Infostat usando ANOVA (variables continuas) y chi cuadrado (categóricas), p≤0,05. Se respetaron la confidencialidad y anonimato. Datos poblacionales: 56%mujeres/44%varones. 42% de la población total padecía obesidad y 39,8% DM2. 390 pacientes con cáncer en el período. Prevalencia general cáncer=8,5%, mortalidad=27,5 ‰, letalidad=32%. Sobrevida promedio: 2544,44 días. Prevalencias entre pacientes con y sin DM2, y entre sexos fueron similares, pero más elevada en obesos (58vs42%). Tumores más frecuentes: femeninos: mama (0,44) y colon (0,10); masculinos: próstata (0,36) y colon (0,17). Comparaciones entre pacientes con y sin DM2: -Prevalencias (‰): -Mayores en grupo con DM2: Hombres: páncreas (1,31vs0,44), riñón (1,31vs0,44) y Linfoma no Hodgkin (0,87vs0,44); Mujeres: mama (11,15vs8,31), páncreas (1,75vs0) y endometrio (1,53vs0,87). -Más elevadas en grupo sin DM2: Hombres: próstata (7vs4,37), colon (3,28vs2,84) y vejiga (1,97vs0,87); Mujeres: colon (3,06vs1,31), tiroides (1,09vs0,44) y melanoma (1,09vs0,22). –Edad de diagnóstico (años): en hombres con DM2 se hallaron a edades más tempranas cáncer de colon (68,91vs75,87) y próstata (71,78vs77,74). –Mortalidad: Los valores fueron similares en mujeres con y sin DM2 (RR:1,01; OR:1,02). En hombres fue menor para DM2 (RR:0,74; OR:0,57). Los de mayor mortalidad en pacientes con DM2 fueron: mama>colon>próstata>páncreas. –Letalidad (%): mayor en pacientes DM2 para cáncer gástrico (100vs50), mientras que esófago, colon, riñón y próstata fueron mayores en el grupo sin DM2. –Sobrevida (días): mujeres sin DM2 tienen una sobrevida mayor (4213,5vs1802,73). La existencia de DM2 en comorbilidad con el cáncer afecta significativamente los parámetros estudiados principalmente en mujeres, ya que el cáncer de mama tuvo mayor prevalencia en mujeres con DM2, y estas tuvieron una sobrevida menor. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2023-10-19 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/42713 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 80 (2023): Suplemento JIC XXIV Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 80 (2023): Suplemento JIC XXIV Revista da Faculdade de Ciências Médicas de Córdoba; v. 80 (2023): Suplemento JIC XXIV 1853-0605 0014-6722 spa https://revistas.unc.edu.ar/index.php/med/article/view/42713/42881 Derechos de autor 2023 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |